Animal Cell, Per Se (e.g., Cell Lines, Etc.); Composition Thereof; Process Of Propagating, Maintaining Or Preserving An Animal Cell Or Composition Thereof; Process Of Isolating Or Separating An Animal Cell Or Composition Thereof; Process Of Preparing A Composition Containing An Animal Cell; Culture Media Therefore Patents (Class 435/325)
  • Patent number: 10662411
    Abstract: Cultivating a pluripotent stem cell in a medium comprising at least one member selected from the group consisting of ethanolamine, an ethanolamine analog, and a pharmaceutically acceptable salt thereof, and which is substantially free of ?-mercaptoethanol or contains ?-mercaptoethanol at a concentration of not more than 9 ?M, and the like, is effective for the proliferation of a pluripotent stem cell while maintaining an undifferentiated state.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: May 26, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Sho Senda, Tomomi Yoshida, Satoru Okamoto, Yoko Kuriyama, Manabu Kitazawa, Ikue Harata, Nao Sugimoto
  • Patent number: 10633655
    Abstract: The present invention features compositions and methods relating to tRNA-derived small RNAs (tsRNAs). Provided herein are oligonucleotide compositions that are complementary to tsRNAs, in particular leuCAGtsRNA, and methods of using the oligonucleotides for the regulation of respective tsRNA. Further provided are methods of inducing apoptosis through the inhibition of leuCAGtsRNA.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Hak Kyun Kim, Shengchun Wang
  • Patent number: 10627403
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • Patent number: 10626366
    Abstract: Stem cells such as embryonic stem cells (ES cells), including human ES cells, are cultured in a medium comprising a ROCK inhibitor, and a stem cell culture medium, optionally serum free, comprises a ROCK inhibitor.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 21, 2020
    Assignee: RIKEN
    Inventors: Yoshiki Sasai, Kiichi Watanabe
  • Patent number: 10612004
    Abstract: An in vitro skin equivalent includes at least one epidermis equivalent and at least one dermis equivalent, and further includes melanocytes constitutively producing melanin and fibroblasts.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: April 7, 2020
    Assignee: L'OREAL
    Inventors: Christine Duval, Françoise Bernerd
  • Patent number: 10612002
    Abstract: Provided herein are methods that enable the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post-facto enrichment.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 7, 2020
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Charles E. Murry, Lil Pabon, Nathan Palpant
  • Patent number: 10610980
    Abstract: A self-heating solder flux material includes a solder flux material and a multi-compartment microcapsule. The solder flux material includes a solvent carrier, and the multi-compartment microcapsule includes a first compartment, a second compartment, and an isolating structure. The first compartment contains a first reactant, and the second compartment contains a second reactant. The isolating structure separates the first compartment from the second compartment. The isolating structure is adapted to rupture in response to a stimulus.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: April 7, 2020
    Assignee: International Business Machines Corporation
    Inventors: Eric J. Campbell, Sarah K. Czaplewski-Campbell, Joseph Kuczynski, Timothy J. Tofil
  • Patent number: 10611998
    Abstract: This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of differentiation factors and mitogens can be used to produce cell populations bearing markers of oligodendrocyte precursor cells. Upon further differentiation form complex processes characteristic of mature oligodendrocytes. The cells are capable of forming myelin sheaths, and can be used therapeutically improve function of the central nervous system.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: April 7, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Hans S. Keirstead, Gabriel I. Nistor
  • Patent number: 10611994
    Abstract: A device for monitoring a cell culture includes one or more electrochemical sensors configured to be positioned adjacent to or embedded within a medium of a cell culture. The one or more electrochemical sensors are configured to generate signals in accordance with the cell culture. A data storage device is configured to receive and store the signals from the one or more electrochemical sensors. A computation device is configured to analyze the signals from the one or more electrochemical sensors to determine cell activity over time using sensitivity information.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: April 7, 2020
    Assignee: International Business Machines Corporation
    Inventors: Amos Cahan, Guy M. Cohen, Theodore G. van Kessel, Sufi Zafar
  • Patent number: 10597624
    Abstract: Algae cultivation systems and methods account for weather variations that can affect algae cultivation. In one system, an open raceway algae cultivation system includes a channel having a high section and a low liquid collection section. The channel is sloped to allow substantially all of an algae cultivation fluid in the high section to flow downwardly into the low liquid collection section. A barrier is removably positioned in the high section and a drain is positioned in the high section such that, when substantially all of the algae cultivation fluid has collected in the low liquid collection section, any rainwater that falls in the high section flows into the drain, without the rainwater mixing with the algae cultivation fluid in the low liquid collection section.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: March 24, 2020
    Assignee: GLOBAL ALGAE TECHNOLOGIES, LLC
    Inventors: David A. Hazlebeck, Rodney Corpuz
  • Patent number: 10597661
    Abstract: The invention relates to polynucleotide agents targeting a Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such polynucleotide agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 24, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Patent number: 10584364
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 10, 2020
    Assignee: Rgeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
  • Patent number: 10576101
    Abstract: The present invention relates to roneparstat for use in a combined therapy for the treatment of multiple myeloma. In particular it has unexpectedly been found that the combined use of roneparstat with a proteasome inhibitor, in particular selected between bortezomib and carfilzomib or with melphalan improve efficacy in decreasing the overall tumor burden, especially showing synergism, with respect to the administration of each active ingredient alone.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 3, 2020
    Assignees: Leadiant Biosciences SA, The UAB Research Foundation
    Inventors: Ralph D. Sanderson, Vishnu Prakash C. Ramani, Alessandro Noseda, Paola Barbieri
  • Patent number: 10577606
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of PHD2 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against PHD2 gene expression.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: March 3, 2020
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Brandon Ason, Duncan Brown, Walter R. Strapps
  • Patent number: 10570391
    Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: February 25, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin Maier, Satyanarayana Kuchimanchi, Klaus Charisse
  • Patent number: 10561714
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 18, 2020
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Patent number: 10557121
    Abstract: Provided is a method for producing chondrocytes from pluripotent stem cells, the method comprising the steps of: (i) culturing pluripotent stem cells under adherent conditions in a medium containing an HMG-CoA reductase inhibitor and one or more substances selected from the group consisting of BMP2, TGF? and GDF5, and (ii) culturing the cells obtained in step (i) under suspension conditions in a medium containing an HMG-CoA reductase inhibitor and one or more substances selected from the group consisting of BMP2, TGF? and GDF5. Also provided is a pharmaceutical product comprising chondrocytes obtained by the method.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 11, 2020
    Assignee: Kyoto University
    Inventor: Noriyuki Tsumaki
  • Patent number: 10550366
    Abstract: The present invention relates to a cell culture support including a substrate and a thermoresponsive polymeric blend layer, wherein the polymeric blend layer includes at least one thermoresponsive polymer and at least one network forming adhesion promoter. The present invention further relates a method of making a cell culture complex including: providing a substrate; blending at least one thermoresponsive polymer and at least one network forming adhesion promoter to provide a polymeric blend; applying a thin film of said polymeric blend to the substrate to provide a polymeric blend layer on the substrate; curing the polymeric blend layer on the substrate to provide a cell culture support; and depositing cells onto said cell culture support, wherein the cells may optionally further include medium, to provide a cell culture complex.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 4, 2020
    Assignee: THE UNIVERSITY OF AKRON
    Inventors: Bi-Min Newby, Nikul Patel, John Cavicchia, Ge Zhang
  • Patent number: 10550197
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • Patent number: 10542743
    Abstract: The present invention relates to a method of isolating mesenchymal stem cells originated from Wharton's jelly (WJ-MSC) from single donor. The method for isolating and proliferating viable cells from Wharton's jelly wherein the method includes the steps of (a) obtaining umbilical cord tissue comprising of viable cells from Wharton's jelly, (b) isolating the viable cells in a sample collection media, (c) preparing a primary stock culture using the viable cells from step (b), (d) proliferating the primary stock culture from step (c) to obtain sub-cultured stocks, (e) harvesting the viable cells from the sub-cultured stocks from step (d) and (f) cryo-preserving the viable cells from step (e) under cryogenic conditions.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: January 28, 2020
    Assignee: HYGIEIA THERAPEUTICS SDN BHD
    Inventors: Vijayendran Govindasamy, Wijenthiran Kunasekaran, Naresh Waran Gnanasegaran
  • Patent number: 10539567
    Abstract: Disclosed are methods for detecting remnant cancer cells in a tissue sample.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: January 21, 2020
    Assignee: Indicator Systems International, Inc.
    Inventors: Gerald F. Swiss, John V. Fante, Robert M. Moriarty, Richard J. Pariza
  • Patent number: 10533175
    Abstract: Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides. Such compounds and methods are useful to treat, prevent, or ameliorate spinocerebellar ataxia type 3 (SCA3) in an individual in need thereof.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: January 14, 2020
    Assignees: Ionis Pharmaceuticals, Inc., Academisch Ziekenhuis Leiden
    Inventors: Frank Rigo, Thazha P. Prakash, Wilhelmina Maria Clasina Van Roon-Mom, Lodewijk Julius Anton Toonen
  • Patent number: 10519444
    Abstract: Inhibitory nucleic acids, e.g., antisense oligonucleotides (ASO) against PAR-TERRA RNA or other chromosome-specific TERRA transcripts (i.e., inclusive of chromosome-specific subtelomeric sequences), and methods of use thereof to downregulate expression of escapee genes on the inactive X chromosome, expression from the active X chromosome, subtelomeric autosomal loci (e.g., FSHD locus), or expression of autosomal genes involved in growth control and apoptosis, e.g., in cells and subjects with supernumerary X chromosomes and/or cancer and other human diseases.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 31, 2019
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Hsueh-Ping Chu
  • Patent number: 10519440
    Abstract: This invention generally relates to a composition and method of using recombinant microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA) as therapeutic drugs for treating Alzheimer's diseases (AD). More specifically, the present invention relates to the use of man-made miRNA miR-302 precursors (pre-miR-302) for AD therapy in humans. These pre-miR-302 molecules can be mass produced in prokaryotes as a form of DNA expression-competent DNA vectors and/or hairpin-like RNAs. As prokaryotic cells do not transcribe or process hairpin-like RNAs, the present invention also teaches a method for expressing pre-miRNAs in prokaryotes, i.e. pro-miRNA, using a novel hairpin-like RNA transcription mechanism newly found in prokaryotes.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: December 31, 2019
    Inventors: Chih-Li Lin, Hsin-Hua Li, Shi-Lung Lin, Te-Jen Lai
  • Patent number: 10500233
    Abstract: Briefly stated, the present invention provides compositions and methods for treating or preventing joint injuries utilizing hair follicle derived Non-Bulbar Dermal Sheath (“NDBS”) cells. Within one aspect of the invention methods are provided for isolating NBDS cells, comprising the steps of: (a) preparing vital hair; (b) cleaving the hair prepared in step (a) to remove the hair follicle bulb; (c) isolating Non-Bulbar Dermal Sheath tissue; and (d) cultivating the isolated Non-Bulbar Dermal sheath tissue to produce NBDS cells. Within one embodiment of the invention the vital hair is obtained by full skin biopsy from the occipital scalp of a subject.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: December 10, 2019
    Assignee: RepliCel Life Sciences Inc.
    Inventors: Rolf Hoffmann, Kevin John McElwee
  • Patent number: 10501726
    Abstract: The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lig28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: December 10, 2019
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Steven L Stice, Franklin West, Yangqing Lu
  • Patent number: 10494636
    Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: December 3, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
  • Patent number: 10487310
    Abstract: Provided are a culture vessel with which an embryonic body can be formed efficiently from human embryonic stem cells, and a method for culturing human embryonic stem cells using the vessel. There is provided a vessel for culturing human embryonic stem cells, the culture vessel having two or more wells (1), wherein each of the wells (1) has a tubular body (2) and a funnel-shaped bottom (3) provided at one end of the body (2), the bottom (3) being a concave curved surface at the center (4) of the bottom (3) and the bottom (3) having an opening angle (?) in range of 60 to 100°. There is provided a method for culturing human embryonic stem cells by using said vessel for culturing human embryonic stem cells.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: November 26, 2019
    Assignees: RIKEN, SUMITOMO BAKELITE CO., LTD.
    Inventors: Yoshiki Sasai, Keiko Muguruma, Ryouhei Tsukada, Hayao Tanaka
  • Patent number: 10478168
    Abstract: Devices and methods for treating an abdominal incision or hernia are described. An implant for the restoration or prophylactic treatment of an abdominal wall comprises an elongate element and at least one sheet connected to the elongate element along a longitudinal axis of the elongate element. The elongate element is positioned along the line of incision, and the at least one sheet is secured to the abdominal muscles surrounding the incision.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: November 19, 2019
    Assignee: LifeCell Corporation
    Inventors: Wenquan Sun, Gary Monteiro
  • Patent number: 10473641
    Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: November 12, 2019
    Assignee: Stemina Biomarker Discovery, Inc.
    Inventors: Paul R. West, April M. Weir-Hauptman, Alan M. Smith, Elizabeth L. R. Donley, Gabriela G. Cezar
  • Patent number: 10464989
    Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: November 5, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • Patent number: 10451621
    Abstract: The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: October 22, 2019
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Anuradha Dixit, Kenton B. Abel, Swati Gupta, Ester Fernandez-Salas
  • Patent number: 10441611
    Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: October 15, 2019
    Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATION
    Inventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
  • Patent number: 10441957
    Abstract: The present invention relates to a magnetic particle separating device, and a method of separating and purifying nucleic acid or protein using the same. The device comprises: induction magnets (100); an induction magnet fixing part (200) having induction magnet fixing holes (210) for fixing the induction magnets (100); and a body (300) in which entry holes (310) are formed into which tubes (T) are inserted. Thus, the application and removal of a magnetic field to and from the body is made very convenient, so that the device can be very advantageously used in the separation and purification of nucleic acid or protein.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: October 15, 2019
    Assignee: BIONEER CORPORATION
    Inventors: Han Oh Park, Jong Kab Kim
  • Patent number: 10435709
    Abstract: A nucleic acid containing a dopamine receptor type 2-specific promoter (D2SP) is provided. In certain embodiments, the nucleic acid includes a dopamine receptor type 2-specific promoter (D2SP), wherein the D2SP does not include exon 1 of a D2 receptor gene, wherein the D2SP comprises a Kozak sequence, and wherein the D2SP includes a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1. Also provided are expression vectors, genetically modified host cells and kits that include the subject nucleic acid.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 8, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl A. Deisseroth, Charu Ramakrishnan, Kelly Zalocusky
  • Patent number: 10435677
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic stem cell.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 8, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Jeffrey C. Miller, Lei Zhang
  • Patent number: 10435666
    Abstract: The first method to cause a culture of human and other primate stem cells to directly and uniformly differentiate into a committed cell lineage is disclosed. Treatment of primate stem cells with a single protein trophoblast induction factor causes the cells to transform into human trophoblast cells, the precursor cells of the placenta. Several protein factors including bone morphogenic protein 4 (BMP4), BMP2, BMP7, and growth and differentiation factor 5 can serve as trophoblast-inducting factors.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: October 8, 2019
    Assignee: WiCell Research Institute, Inc.
    Inventors: Ren-He Xu, James A. Thomson
  • Patent number: 10413564
    Abstract: Compositions and methods for reducing or overcoming acquired resistance to cetuximab are provided. Compositions and methods for treatment of cetuximab-resistant cancers are also provided. In addition, methods of inhibiting the growth of EGFR-expressing tumor cells that are resistant to cetuximab therapy are provided herein.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: September 17, 2019
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: Muh-Hwa Yang, Dennis Shin-Shian Hsu
  • Patent number: 10415015
    Abstract: In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-AB/C, ICOS-L, and CD58, and wherein the one or more viral vectors comprise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and/or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and/or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 17, 2019
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Anand Veerapathran, Aishwarya Gokuldass, Brian Rabinovich, Michael T. Lotze
  • Patent number: 10400029
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: September 3, 2019
    Assignee: Inhibrx, LP
    Inventors: Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
  • Patent number: 10400214
    Abstract: This application provides for enriched target populations oligodendrocyte precursor cells (OPCs) that can differentiate into oligodendrocytes. The target OPCs may be expanded and optionally subjected to conditions to induce their differentiation into oligodendrocytes. The target OPCs and their progeny are useful for the treatment of disease associated with demyelination of central nervous system axons.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 3, 2019
    Assignee: BOCO SILICON VALLEY, INC.
    Inventors: Alexandra Capela, Nobuko Uchida
  • Patent number: 10400219
    Abstract: Engineered, living, three-dimensional liver tissue constructs including: one or more layers, wherein each layer contains one or more liver cell types, the one or more layers cohered to form a living, three-dimensional liver tissue construct free of pre-formed scaffold. Also disclosed are arrays and methods of making the same.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 3, 2019
    Assignee: Organovo, Inc.
    Inventors: Benjamin R. Shepherd, Justin B. Robbins, Vivian A. Gorgen, Sharon C. Presnell
  • Patent number: 10400238
    Abstract: The invention relates to polynucleotide agents targeting the complement component C5 gene, and methods of using such polynucleotide agents to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: September 3, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Patent number: 10398738
    Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: September 3, 2019
    Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATION
    Inventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
  • Patent number: 10393563
    Abstract: A volumetric measurement system having an imaging device and a light source, where the light source is configured to illuminate the container and the sample regardless of a blockage or obstruction of the sample on at least part of the container.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 27, 2019
    Assignee: Brooks Automation, Inc.
    Inventors: David Charles Lee, Martin G. Short, Melvyn Whiteside, Tim Redburn
  • Patent number: 10385316
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 20, 2019
    Assignees: Baylor College of Medicine, Wilson Wolf Manufacturing
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Patent number: 10385132
    Abstract: The invention relates to polynucleotides, particularly chimeric polynucleotides useful for optimal production of functional immunoglobulins with human idiotypes in rodents. The invention further relates to rodents comprising such polynucleotides.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: August 20, 2019
    Assignee: OPEN MONOCLONAL TECHNOLOGY, INC.
    Inventors: Marianne Bruggemann, Roland Buelow, Michael J. Osborn, Biao Ma
  • Patent number: 10376536
    Abstract: An antisense oligomer capable of binding to a selected target on the ITGA4 gene transcript to modify pre-mRNA splicing in an ITGA4 gene transcript or part thereof.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 13, 2019
    Assignee: MURDOCH UNIVERSITY
    Inventors: Stephen Donald Wilton, Sue Fletcher, May Aung-Htut
  • Patent number: 10377991
    Abstract: This invention provides a method for stably producing airway epithelial cells from pluripotent stem cells. Specifically, the invention relates to a method for producing airway epithelial cells from pluripotent stem cells comprising steps: (1) culturing pluripotent stem cells in a medium containing activin A and a GSK3? inhibitor; (2) culturing the cells obtained in Step (1) in a medium containing a BMP inhibitor and a TGF? inhibitor; (3) culturing the cells obtained in Step (2) in a medium containing BMP4, retinoic acid, and a GSK3? inhibitor; (5) subjecting the cells obtained after Step (3) to three-dimensional culture in a medium containing a GSK3? inhibitor, FGF10, and a ROCK inhibitor; and (6) subjecting the proximal airway epithelial progenitor cells obtained in Step (5) to three-dimensional culture in a medium containing a ROCK inhibitor.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 13, 2019
    Assignee: KYOTO UNIVERSITY
    Inventors: Shimpei Gotoh, Yuki Yamamoto, Satoshi Konishi, Michiaki Mishima
  • Patent number: 10378038
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: August 13, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela